NEW YORK (

TheStreet

) --

BioMarin Pharmaceuticals

(Nasdaq:

BMRN

) hit a new 52-week high Thursday as it is currently trading at $37.88, above its previous 52-week high of $37.82 with 164,282 shares traded as of 10:10 a.m. ET. Average volume has been 840,800 shares over the past 30 days.

BioMarin has a market cap of $4 billion and is part of the

health care

sector and

drugs

industry. Shares are up 9.8% year to date as of the close of trading on Wednesday.

BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions.

  • Sign up for TheStreet's FREE Dividend and Income Investor Newsletter

TheStreet Ratings rates BioMarin as a

hold

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and weak operating cash flow. You can view the full

BioMarin Ratings Report

.

See all

52-week high stocks

or get investment ideas from our

investment research center

.

null